Assessment of IL17BR serum concentration in females with benign & malignant breast tumors

2018 ◽  
Vol 9 (SPL1) ◽  
Author(s):  
Haider Abed Ali Alshawi
Keyword(s):  
Breast Cancer ◽  
Age Groups ◽  
Breast Tumors ◽  
Recurrent Breast Cancer ◽  
Significant Difference ◽  
Malignant Breast ◽  
Healthy Control ◽  
Study Population ◽  
The Mean ◽  
Recurrent Breast

Breast cancer is one of the most dangerous and most common malignanciesamong women in the world, which affects different age groups of women, IL-17 plays an important role in chronic inflammation and cancer, Serum IL-17BR concentration which useful in early diagnosis and staging of breast tumors.The aim of the study was to evaluate of IL-17BR serum concentrations in patients with benign and malignant breast tumors and study the relation between the above parameter and breast cancer development. The study population was composed of 120 samples 24 patients with recently diagnosed breast carcinoma,6 patients with repetitive carcinoma,40 patients with benign breast tumor (fibroadenoma) and 50 normal apparently health woman as a control.ELISA technique was applied for estimation of IL-17BR levels in patients as well as apparently healthy volunteers of women. The results revealed the mean age of malignant breast females was 52.8 ± 12.3 (Mean ± SD),while it was 26.9 ± 8.3 years for women with benign tumor with highly significant difference(P<0.001),IL-17BR level was determined and found that was a highly significant difference in its level among benign breast females subjects (72.48 Ng/ μL) and healthy control (50.87 Ng/ μL) P< 0.001),no significant difference in the mean of sIL-17BR level among the different patients‘ groups (49.83,64.33 Ng/ μL) for recurrent and primary breast cancer respectively.Estimation of IL-17BR level showed significant elevation of the concentration among the sera of recurrent breast cancer in comparison with other groups which perhaps regarded as a prognostic marker.

A study of manual toothbrushing skills in children aged 3 to 11 years

2003 ◽  
Vol 27 (1) ◽  
pp. 91-94 ◽  
Author(s):  
Ali Mentes ◽  
Julide Atukeren
Keyword(s):  
Age Groups ◽  
Age Group ◽  
Age And Gender ◽  
Significant Difference ◽  
Study Population ◽  
The Mean ◽  
And Gender

The aim of the study was to evaluate toothbrushing management and ability of children in relation to age and gender. The study population consisted of 75 children and were divided into three equal groups as 3-5, 6-8 and 9-11 years of age.The grip type during toothbrushing was recorded on videotape.The most preferred grip types were distal (73%) followed by power (43%) and oblique grips (29%). There were a statistically significant differences between age groups and the grip types (p&lt;0.001) but no significant difference was seen between boys and girls in grip preferences (p&gt;0.05).The mean duration of toothbrushing was shorter in 3-5 years of age group (28 seconds) than the 6-8 and 9-11 age groups (35 and 47 seconds respectively).

Parallel Assessment of Circulatory Cell-Free DNA by PCR and Nucleosomes by ELISA in Breast Tumors

2008 ◽  
Vol 23 (2) ◽  
pp. 69-73 ◽  
Author(s):  
M. Seefeld ◽  
S. El Tarhouny ◽  
A.X.C. Fan ◽  
S. Hahn ◽  
W. Holzgreve ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quantitative Pcr ◽  
Breast Tumors ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serum Samples ◽  
Cell Free Dna ◽  
Free Dna ◽  
Significant Difference ◽  
Malignant Breast ◽  
Benign Breast Tumors

Objectives In order to assess the potential biomolecules for breast cancer, we analyzed in parallel the levels of cell-free glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and cell-free nucleosomes in serum samples from patients with benign and malignant breast tumors. The levels of cell-free DNA obtained by quantitative PCR were compared with those obtained by enzyme-linked immunosorbent assay (ELISA). Methods Twenty-three patients with benign breast tumors, 27 patients with breast cancer, and 32 age-matched healthy women were recruited. The amounts of serum nucleosomes were analyzed by ELISA and the levels of cell-free GAPDH were measured by real-time quantitative PCR. The correlation between nucleosome and cell-free GAPDH levels was examined using the Spearman rank test. Results The levels of cell-free GAPDH were significantly higher in the serum samples of patients with benign and malignant breast tumors than in those of the control group (median 37,966 GE/mL, range 3,802–130,104 versus 11,770 GE/mL, range 2,198–73,522, p=0.035 and median 40,698 GE/mL, range 3,644–192,482 versus 11,770 GE/mL range 2,198–73,522, p=0.001). The concentration of cell-free GAPDH correlated significantly with the quantities of nucleosomes in serum samples (r=0.451, p=0.000). There was, however, no significant difference between healthy individuals and women with benign breast tumors or breast cancer in terms of nucleosomes determined by ELISA. Conclusion Our data suggest that the cell-free serum GAPDH DNA assayed by quantitative PCR is a better biomarker than nucleosomes assayed by ELISA in patients with breast tumors.

Development of a 70 MHz unit for hyperthermia treatment of deep-seated breast tumors

2017 ◽  
Vol 9 (6) ◽  
pp. 1317-1324 ◽  
Author(s):  
Johannes Crezee ◽  
Geertjan Van Tienhoven ◽  
Merel W. Kolff ◽  
Jan Sijbrands ◽  
Gerard Van Stam ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Open Water ◽  
Breast Tumors ◽  
Recurrent Breast Cancer ◽  
Hyperthermia Treatment ◽  
Field Patterns ◽  
Phantom Measurements ◽  
Temperature Controlled ◽  
Recurrent Breast ◽  
Thermocouple Thermometry

A dedicated hyperthermia (HT) system was designed for tumors in intact breast extending beyond the heating depth of our superficial 434 MHz antennas, consisting of a treatment bed fitted with a 50 cm × 40 cm × 16 cm temperature controlled open water bolus. The patient lies in prone position with the breast immersed in the water positioned in front of a 34 cm × 20 cm 70 MHz waveguide operating in the TE10 mode. E-field patterns were measured in a tissue-mimicking phantom. HT was applied once a week with the 70 MHz applicator for six patients treated with thermoradiotherapy for deep lesions of recurrent breast cancer or melanoma. Two 14-sensor thermocouple thermometry probes were placed in catheters to monitor the invasive temperature. Results: Phantom measurements showed sufficient penetration depth up to 10 cm depth. The combination of 300–900 W antenna power and a water temperature of 42°C was well tolerated for the entire session of 1 h and resulted in good tumor temperatures with T90 = 39.8°C, T50 = 41.1°C, and T10 = 42.2°C. No toxicity or complaints were associated with the heating. A water mattress and other measures were needed to assure a comfortable position throughout the treatment. Conclusion: the 70 MHz breast applicator system performed well and tumor temperatures were good.

Profile of anterior gradient 3 (AGR3) mRNA expression and serum levels in benign and malignant breast tumors

2021 ◽  
pp. 1-5
Author(s):  
Prihantono Prihantono ◽  
Warsinggih Rahardjo ◽  
Salman Ardi Syamsu ◽  
Nilam Smaradhania
Keyword(s):  
Breast Cancer ◽  
Mrna Expression ◽  
Serum Protein ◽  
Breast Tumors ◽  
Serum Levels ◽  
Protein Levels ◽  
Qrt Pcr ◽  
Potential Biomarker ◽  
Significant Difference ◽  
Malignant Breast

BACKGROUND: Benign and malignant breast tumors are the most commonly diagnosed tumor in females. Early and accurate diagnosis of malignancy is essential for effective breast cancer treatment. Human anterior gradient 3 (AGR3) has been suggested as a potential biomarker for the early detection and prognostic determination of breast cancer. OBJECTIVE: This study profiles AGR3 mRNA expression and serum protein levels in patients with benign and malignant breast tumors. METHODS: A case-control study was conducted on 40 benign and 40 malignant breast tumor patients in Makassar, Indonesia. AGR3 mRNA and protein were detected using qRT-PCR and ELISA, respectively. RESULTS: This study found significantly higher AGR3 mRNA expression in benign than malignant breast tumors using qRT-PCR (p < 0.001). In contrast, ELISA revealed no significant difference between AGR3 serum protein levels in benign and malignant breast tumors (p = 0.507). CONCLUSIONS: AGR3 is associated with non-aggressive tumors and could be used as a marker for less aggressive breast tumors.

Phase III Study of N,N-Diethyl-2-[4-(Phenylmethyl) Phenoxy]Ethanamine (BMS-217380-01) Combined With Doxorubicin Versus Doxorubicin Alone in Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19

2004 ◽  
Vol 22 (2) ◽  
pp. 269-276 ◽  
Author(s):  
Leonard Reyno ◽  
Lesley Seymour ◽  
Dongsheng Tu ◽  
Susan Dent ◽  
Karen Gelmon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast ◽  
Progression Free Survival ◽  
Recurrent Breast Cancer ◽  
Phase Iii ◽  
Metastatic Breast Carcinoma ◽  
Significant Difference ◽  
Recurrent Breast

Purpose N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine (DPPE; tesmilifene) is a novel agent that augments chemotherapy cytotoxicity in vitro and in vivo. A phase II trial combining DPPE and doxorubicin (DOX) in metastatic breast carcinoma showed increased response over that expected with DOX. We report a phase III trial comparing DOX with DPPE plus DOX in metastatic or recurrent breast cancer. Patients and Methods Anthracycline-naive women with measurable metastatic disease were randomly assigned to receive, every 21 days, either DOX 60 mg/m2 intravenously or DOX during the last 20 minutes of an 80-minute infusion of DPPE (5.3 mg/kg), in both cases to cumulative DOX doses of 450 mg/m2. Patients receiving DPPE were aggressively premedicated to ameliorate toxicity. End points included progression-free survival (PFS), response rate (RR), and response duration (RD), quality of life (QOL), toxicity, and overall survival (OS). Results A planned interim analysis failed to detect an RR difference more than 5%. The study was closed to additional accrual and all DPPE was discontinued. The final analysis was conducted as planned after 256 progression events (median follow-up, 20.5 months). There was no significant difference in RR, RD, or PFS between arms. DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P = .021). DPPE plus DOX was associated with more gastrointestinal and CNS toxicity. No consistent influence on QOL was detected. Conclusion This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX. Additional studies of DPPE are warranted.

Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose.

1996 ◽  
Vol 14 (6) ◽  
pp. 1848-1857 ◽  
Author(s):  
N Avril ◽  
J Dose ◽  
F Jänicke ◽  
S Bense ◽  
S Ziegler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Pet Imaging ◽  
Breast Imaging ◽  
Breast Tumors ◽  
Partial Volume Correction ◽  
Partial Volume ◽  
Volume Correction ◽  
Fdg Uptake ◽  
Significant Difference ◽  
Malignant Breast

PURPOSE To evaluate the diagnostic value of position emission tomographic (PET) imaging with F-18 fluorodeoxyglucose (FDG) in differentiating between benign and malignant breast tumors. PATIENTS AND METHODS Fifty-one patients, with suspicious breast lesions newly discovered either by physical examination or by mammography, underwent PET imaging before exploratory surgery. FDG-PET images of the breast were analyzed visually and quantitatively for objective assessment of regional tracer uptake. RESULTS Primary breast cancer was identified visually with a sensitivity of 68% to 94% and a specificity of 84% to 97% depending on criteria used for image interpretation. Quantitative analysis of FDG uptake in tumors using standardized uptake values (SUV) showed a significant difference between benign (1.4 +/- 0.5) and malignant (3.3 +/- 1.8) breast tumors (P < .01). Receiver operating characteristic (ROC) curve analysis exhibited a sensitivity of 75% and a specificity of 100% at a threshold SUV value of 2.5. Sensitivity increased to 92% with a corresponding specificity of 97% when partial volume correction of FDG uptake was performed based on independent anatomic information. CONCLUSION PET imaging allowed accurate differentiation between benign and malignant breast tumors providing a high specificity. Sensitivity for detection of small breast cancer ( < 1 cm) was limited due to partial volume effects. Quantitative image analysis combined with partial volume correction may be necessary to exploit fully the diagnostic accuracy. PET imaging may be helpful as a complimentary method in a subgroup of patients with indeterminate results of conventional breast imaging.

Age as a prognostic factor in recurrent breast cancer.

1986 ◽  
Vol 4 (5) ◽  
pp. 663-671 ◽  
Author(s):  
G Falkson ◽  
R S Gelman ◽  
F J Pretorius
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Prognostic Factor ◽  
Menopausal Status ◽  
Eastern Cooperative Oncology Group ◽  
Age Groups ◽  
Recurrent Breast Cancer ◽  
Cox Proportional Hazards Model ◽  
Survival Times ◽  
Recurrent Breast

The effect of age as a prognostic factor in recurrent breast cancer was studied in 1,168 patients treated on Eastern Cooperative Oncology Group (ECOG) protocols. Survival was significantly shorter in patients less than 35 years of age (P = .03). This was true even when other good prognostic factors were present. Eighteen prognostic factors were analyzed, and the effect on survival in each of six age groups was studied. Patients with better performance status, less than three sites of metastases, and without visceral or nodal metastases had a better survival time. A Cox proportional hazards model of survival showed that younger age groups, irrespective of menopausal status, had shorter survival times. The predicted median survival times after the first recurrence were 491 days for patients less than 35 years of age, 590 days for patients 36 to 45 years of age, and 700 days for those greater than 45 years of age.

scholarly journals Maximum mouth opening in healthy children and adolescents in Istanbul

2018 ◽  
Vol 6 (1) ◽  
Author(s):  
Mine Koruyucu ◽  
Derya Tabakcilar ◽  
Figen Seymen ◽  
Koray Gençay
Keyword(s):  
Age Groups ◽  
Clinical Signs ◽  
Mouth Opening ◽  
Healthy Children ◽  
Class Iii ◽  
Age Related ◽  
Significant Difference ◽  
Study Population ◽  
Interincisal Distance ◽  
The Mean

Objectives: Mouth opening capacity is often regarded as one of the important parameters for evaluating the function of the temporomandibular joint (TMJ) and masticatory muscle status. A reduced mouth opening capacity may be one of the first clinical signs of TMJ involvement. The purpose of this study was to create age related percentiles for the maximal interincisal distance (MID) of healthy children. Methods: The patients admitted for routine dental examinations to Istanbul University Faculty of Dentistry, Department of Pedodontics were included in this study. The interincisal measurements were performed with metallic calliper and also malocclusions were recorded for all children. Oneway Anova test, Tukey HDS test, Tamhane’s T2 test and Student t test were used for statistical analysis. Results: The study population comprised of 1059 (569 males, 490 females), 3-to 15-year-old (mean age 8.82±3.06) children. The mean score of maximal inter-incisal distance was found 33.24±5.54 for females; 33.32±5.71 for males. There was no statistically significant difference according to gender (p=0.815; p>0.05). The mean score of maximal inter-incisal distance was found 28.63±4.34 for 3-5 years; 33.52±4.84 for 6-11 years; 37.35±5.52 for 12-15 years children. Statistically significant differences were found between age groups (p: 0.001; p<0.01). The mean score of maximal inter-incisal distance was found 32.9±5.6 for class I; 34.92±5.51 for class II; 35.2±5.36 for class III malocclusions. Statistically significant differences were found between malocclusion groups (p:0.001; p<0.01). Conclusion: The result of this study indicated that positive relationship between the maximum mouth opening and age and malocclusion.

ER, PR & HER2 Receptor status in recurrent breast cancer: Its relation to age & time of recurrence

2020 ◽  
Vol 22 (1) ◽  
pp. 16-20
Author(s):  
Abu Khaled Muhammad Iqbal ◽  
Nasima Akhter ◽  
Hasan Shahrear Ahmed ◽  
Md Rassell ◽  
AMM Yahia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Treatment Approach ◽  
Recurrent Breast Cancer ◽  
Breast Cancer Patients ◽  
Her2 Receptor ◽  
Younger Patients ◽  
Receptor Status ◽  
Increased Risk ◽  
Neoplastic Lesions ◽  
Recurrent Breast

Background: Malignant neoplastic lesions of the breast are one of the main causes of cancer death among women. In tumor cells the expression status of Estrogen receptor (ER), progesterone receptor (PR), and c-ERBB2 (HER2/neu) are therapeutically and prognostically important markers affecting the treatment approach, management and prognosis of breast carcinoma. Objective: To explore the relation of receptor status in recurrent breast cancer to age and time of recurrence. Methods: This study was conducted in National Institute of Cancer Research and Hospital (NICRH) and included 81 female patients between 20 to 75 years with recurrent breast cancer. Detection of receptor status of ER +ve/-ve, PR +ve/-ve, Her-2+ve/-ve was based on the immunohistochemistry staining of tissue samples of malignant neoplastic lesions prepared from tissue biopsies of patients with recurrent breast cancer. All the information were recorded through the pre-structured data collection sheet and analyzed. Results: This study showed that most of the recurrent breast cancer patients were Triple negative breast cancer (TNBC) (39.5%) and among them most of them were younger patients. Younger patients with TNBC had increased risk of recurrence. Most of the recurrence occurred within 1-2 years. Conclusion: It can be concluded that the assessment of the expression of these biornarkers in recurrent tumors provides reliable information for the treatment approach of locoregional tumors. Journal of Surgical Sciences (2018) Vol. 22 (1): 16-20

Sign in / Sign up

Export Citation Format

Share Document